Search results
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 days agoA Phase 3 study is already underway with the initial results expected later this decade. But at...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Coronado Eagle & Journal· 4 days agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the
Nisa Investment Advisors LLC Has $29,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
ETF DAILY NEWS· 6 days agoNisa Investment Advisors LLC lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 10,740.0% during the fourth quarter, according to its most recent 13F filing with ...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 4 days agoLagevrio (molnupiravir) generated sales of $350 million in the first quarter, down 5% year over...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoTurning...grew 24% to $6.9 billion driven by increased uptake from earlier-stage cancers and continued strong demand from metastatic indications....
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 4 days agoThe NDA is supported by results from JUPITER-02, a randomized, double...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 7 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 4 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...